annb0t
Top 20
Key Insights
ResMed's estimated fair value is US$178 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to be 21% overvalued based on current share price of US$216 Analyst price target for RMD is US$256, which is 44% above our fair value estimate
How far off is ResMed Inc. (NYSE:RMD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. On...
>>> Read more: Is ResMed Inc. (NYSE:RMD) Worth US$216 Based On Its Intrinsic Value?
ResMed's estimated fair value is US$178 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to be 21% overvalued based on current share price of US$216 Analyst price target for RMD is US$256, which is 44% above our fair value estimate
How far off is ResMed Inc. (NYSE:RMD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. On...
>>> Read more: Is ResMed Inc. (NYSE:RMD) Worth US$216 Based On Its Intrinsic Value?
